Not checked for notices yet.

389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy

Enriqueta Felip, Mario Sznol, Harriet Kluger and 14 more (opens in a new tab)

Journal for ImmunoTherapy of Cancer · 2021

doi:10.1136/jitc-2021-sitc2021.389 (opens in a new tab)

Cited by papers we hold 1

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets · 2025
No notice

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.